Karyopharm Therapeutics Inc.
KPTI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001503802
In the last 90 days, Karyopharm Therapeutics Inc. insiders filed 0 open-market purchases and 2 sales; 96 institutions reported holding it in 13F filings for Q2 2026, worth $206.8M in total; no superinvestor holds it.
Holders of 5% or more of KPTI
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Karyopharm Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 13.80%2.30M shares | +5.40 ppfrom 8.40% | Aug 14, 20252 filings | Nov 7, 2025 | SEC |
| Opaleye Management Inc. | 13G | 9.48%1.57M shares | New | Oct 17, 20251 filing | Oct 17, 2025 | SEC |
| Affinity Asset Advisors, LLC | 13G | 7.83%664.2K shares | New | Apr 10, 20251 filing | Apr 10, 2025 | SEC |
| Adage Capital Management, L.P. | 13G | 5.18%6.55M shares | New | Feb 12, 20251 filing | Feb 12, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Karyopharm Therapeutics Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 202510:45 AM ET | Highbridge Capital Management LLC | 13G/A | 4.90%650.0K shares | –Below 5% | Sep 30, 2025 | SEC |
| Nov 7, 20251:02 PM ET | T. Rowe Price Investment Management, Inc. | 13G/A | 13.80%2.30M shares | +5.40 ppfrom 8.40% | Oct 31, 2025 | SEC |
| Nov 3, 20254:30 PM ET | J. Wood Capital Advisors LLCand 1 other | 13G/A | 4.99%1.00M shares | –Below 5% | Oct 14, 2025 | SEC |
| Oct 30, 20253:18 PM ET | Vanguard Group Inc | 13G/A | 4.70%408.2K shares | –Below 5% | Sep 30, 2025 | SEC |
| Oct 17, 20254:05 PM ET | Opaleye Management Inc.and 2 others | 13G | 9.48%1.57M shares | New | Oct 10, 2025 | SEC |
| Oct 17, 20251:55 PM ET | JPMorgan Chase & Co | 13G/A | 4.90%427.6K shares | −0.30 ppfrom 5.20%Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 202512:12 PM ET | T. Rowe Price Investment Management, Inc. | 13G | 8.40%728.8K shares | New | Jun 30, 2025 | SEC |
| Jul 16, 20259:34 AM ET | JPMorgan Chase & Co | 13G | 5.20%450.4K shares | New | Jun 30, 2025 | SEC |
| Apr 10, 20255:23 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G | 7.83%664.2K shares | New | Apr 3, 2025 | SEC |
| Feb 12, 20259:36 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 5.18%6.55M shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Karyopharm Therapeutics Inc. shares.
No Form 144 notices for Karyopharm Therapeutics Inc. are on file.